Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review

Querrer, Raiza; Ferrare, Nathália; Melo, Nilce Santos de; Stefani, Cristine Miron; Reis, Paula Elaine Diniz dos; Mesquita, Carla Ruffeil Moreira; Borges, Gabriel Álvares; Leite, André Ferreira; Figueiredo, Paulo Tadeu de Souza

doi:10.1007/s00520-020-05855-6

Cited by 22 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Querrer et al (2021) [57] An increase in bone sequestra, cortical bone lysis, and bone density was observed in bisphosphonate-related ONJ, while larger bone sequestra, more frequent periosteal reactions, and mandibular canal enhancement were noted in denosumab-related ONJ.…”

Section: Non-interventional Reviews Author Resultsmentioning

confidence: 99%

18 Years of Medication-Related Osteonecrosis of the Jaw (MRONJ) Research: Where Are We Now?—An Umbrella Review

et al. 2021

View full text Add to dashboard Cite

Background: Osteonecrosis of the jaw (ONJ) is a condition affecting patients exposed to medications used to treat benign and malignant conditions of bone tissue. Many studies have highlighted that ONJ is a severe condition, which is very challenging to manage, especially in individuals with oncologic disease. The aim of this umbrella review is to analyze all available interventional and non-interventional systematic reviews published on medication-related osteonecrosis of the jaw (MRONJ) and summarize this evidence. Material and methods: A multi-database search (PubMed, MEDLINE, EMBASE and CINAHL) was performed to identify related multi-language papers published from January 2003 until June 2021. An additional manual search was also performed in systematic review registries (PROSPERO, INPLASY, JBI and OFS) to identify possible missing reviews. Data were extracted from relevant papers and analyzed according to the outcomes selected in this review. Results: The search generated 25 systematic reviews eligible for the analysis. The total number of patients included in the analysis was 80,840. Of the reviews, 64% (n = 16) were non-interventional and 36% (n = 9) were interventional. Study designs included case series 20.50% (n = 140), retrospective cohort studies 12.30% (n = 84) and case reports 12.20% (n = 83). It was unclear what study design was used for 277 studies included in the 25 systematic reviews. Conclusions: The data reviewed confirmed that the knowledge underpinning MRONJ in the last 20 years is still based on weak evidence. This umbrella review highlighted a widespread low-level quality of studies and many poorly designed reviews.

show abstract

Section: Non-interventional Reviews Author Resultsmentioning

confidence: 99%

18 Years of Medication-Related Osteonecrosis of the Jaw (MRONJ) Research: Where Are We Now?—An Umbrella Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Quando os osteoclastos aderem à superfície óssea para iniciar a reabsorção, liberam enzimas que acidificam o ambiente e promovem a degradação óssea. Estes degradados ricos em BFs são fagocitados pelos osteoclastos inibindo a reabsorção óssea pela inativação da via da síntese do colesterol dentro da célula, reduz a atividade celular ou promove a apoptose, interrompendo assim, o ciclo dos osteoclastos (Querrer et al, 2021;Papapoulos, 2008).…”

Section: Resultsunclassified

“…As características imagenológicas podem diferir a depender da droga empregada (Querrer et al, 2021) e do grau de compromentimento clínico (Kim et al,2020). O acompanhamento imagenológico é recomendado (Moreno-Rabié, et al, 2020) desde antes do início terapêutico, sendo possível observar espessamento da lâmina dura (Cardoso et al,2017), osteoesclerose (Arce et al, 2009), falha da remodelação óssea (Moinzadeh et al, 2013), aumento do espaço do ligamento periodontal e da densidade trabecular, cicatrização deficiente de alvéolos pós-extração, formação de sequestros ósseos, alargamento do canal mandibular e/ou do assoalho do seio maxilar, fistulas oroantrais, fístulas oronasais (Wasserzug et al, 2017) e neoformação óssea periosteal (Brozoski et al, 2012;Fliefel et al, 2015).…”

unclassified

Bifosfonatos e as repercussões nos maxilares: Uma revisão narrativa

Gatis

Silva

Ribeiro

et al. 2021

RSD

View full text Add to dashboard Cite

Os Bifosfonatos são fármacos que atuam diminuindo e inibindo a atividade osteoclástica, e induzindo a apoptose celular. Bloqueiam a diferenciação dos osteoclastos e estimulam os osteoblastos, acarretando a diminuição da reabsorção óssea. Podendo contribuir para exposição de osso necrótico na região bucomaxilofacial. Desta forma, a presente revisão narrativa propõe uma breve discussão, acerca do desenvolvimento da osteonecrose dos ossos maxilares decorrentes da terapia com bifosfonatos. Tendo como temática o desenvolvimento da osteonecrose nos maxilares decorrentes do uso dos bifosfonatos, buscou-se através dos MeSH terms e DeCS/MeSH terms, entre 2006 e 2021, artigos no idioma inglês e português indexados na base de dados do MEDLINE/PubMed, Web of Science, LILACS/bvs bem como, através de uma busca manual. Após a análise dos artigos selecionados observou-se que a possibilidade do desenvolvimento da osteonecrose nos ossos maxilares é multifatorial, sendo desta forma imperativo uma abordagem, a estes sítios, de cunho preventivo e com uma terapêutica minimamente invasiva.

show abstract

“…Early signs of disease are maxillary or mandibular sites (mainly post-extractive, but also perimplant site or associated to endodontic sequelae) with delayed healing and persistent mucosal incompetence, following by superinfection and bone sequestrum. ( Figure 15 a,b) [ 130 , 131 , 132 , 133 ], Lesions may be single or multiple, synchronous or metachronous necrotic areas of the jaw, with pus drainage and with or without bone exposure. Overall, any dental procedure may represent a risk factor for MRONJ in patients taking the aforementioned drugs [ 134 ].…”

Section: Drug-induced Oral Lesionsmentioning

confidence: 99%

Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview

2021

View full text Add to dashboard Cite

Many systemic (infective, genetic, autoimmune, neoplastic) diseases may involve the oral cavity and, more generally, the soft and hard tissues of the head and neck as primary or secondary localization. Primary onset in the oral cavity of both pediatric and adult diseases usually represents a true challenge for clinicians; their precocious detection is often difficult and requires a wide knowledge but surely results in the early diagnosis and therapy onset with an overall better prognosis and clinical outcomes. In the current paper, as for the topic of the current Special Issue, the authors present an overview on the most frequent clinical manifestations at the oral and maxillo-facial district of systemic disease.

show abstract

Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review

Cited by 22 publications

References 30 publications

18 Years of Medication-Related Osteonecrosis of the Jaw (MRONJ) Research: Where Are We Now?—An Umbrella Review

18 Years of Medication-Related Osteonecrosis of the Jaw (MRONJ) Research: Where Are We Now?—An Umbrella Review

Bifosfonatos e as repercussões nos maxilares: Uma revisão narrativa

Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview

Contact Info

Product

Resources

About